CAJ | 학술논문

2014年国际T细胞淋巴瘤临床大会主要报告了T细胞淋巴瘤的治疗状况及进展,其中包括靶向表观遗传学在T细胞淋巴瘤中的应用.有研究发现在外周T细胞淋巴瘤(PTCL)中控制DNA和组蛋白甲基化的基因存在突变.根据这一研究结果应用组蛋白去乙酰化酶(HDAC)抑制剂belinostat和romidepsin可使PTCL获得29％～ 38％的总反应率,中位缓解时间为13.6个月.NK/T细胞淋巴瘤是东南亚国家常见的恶性淋巴瘤,在中国和日本占非霍奇金淋巴瘤的15％～ 28％,明显高于欧美国家,主要与亚洲人群EB病毒感染率高有关.应用含左旋门冬酰胺酶的方案如SMILE和AspMetDex方案,可使早期病例长期生存率超过70％,晚期病例可达到近40％.对于PTCL可以将新药如普拉曲沙、罗咪酯肽等联合应用,从而提高完全缓解率.
2014년국제T세포림파류림상대회주요보고료T세포림파류적치료상황급진전,기중포괄파향표관유전학재T세포림파류중적응용.유연구발현재외주T세포림파류(PTCL)중공제DNA화조단백갑기화적기인존재돌변.근거저일연구결과응용조단백거을선화매(HDAC)억제제belinostat화romidepsin가사PTCL획득29％～ 38％적총반응솔,중위완해시간위13.6개월.NK/T세포림파류시동남아국가상견적악성림파류,재중국화일본점비곽기금림파류적15％～ 28％,명현고우구미국가,주요여아주인군EB병독감염솔고유관.응용함좌선문동선알매적방안여SMILE화AspMetDex방안,가사조기병례장기생존솔초과70％,만기병례가체도근40％.대우PTCL가이장신약여보랍곡사、라미지태등연합응용,종이제고완전완해솔.
The treatment status and progress in T cell lymphoma including epigenetic involved mutations that control DNA and histone methylation were reported and intensively discussed in 2014 international T cell lymphoma forum.According to the theory,treatment with HDAC inhibitor belinostat and romidepsin for peripheral T cell lymphoma (PTCL) can achieve 29 ％-38 ％ overall response rate (ORR) and 13.6 months median relief time.NK/T cell lymphoma in southeast asia is a common malignant lymphoma,15 ％-28 ％ of the NHL accounted in China and Japan for,which is significantly higher than that in the European and American countries,mainly related to EB virus widespread infection.L-asparaginase enzymes,such as SMILE and AspMetDex,can make the early cases with more than 70 ％ long-term survival rate,advanced cases with 40 ％ response rate.Some new drugs,such as pralatrexate,combined with romidepsin can be used in PTCL cases to improve the complete remission rate.